ADUS241220P145000
- 0.00
- 0.000.00%
Addus HomeCare Newsroom
Addus HomeCare Initiated at Market Outperform by JMP Securities
Addus HomeCare Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Addus Homecare (ADUS)
JMP Securities Initiates Addus HomeCare(ADUS.US) With Buy Rating, Announces Target Price $150
BofA Securities Maintains Addus HomeCare(ADUS.US) With Buy Rating, Announces Target Price $147
TD Cowen Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $141
TD Cowen Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $141
Addus HomeCare Analyst Ratings
RBC Capital Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $136
RBC Capital Reaffirms Their Buy Rating on Addus Homecare (ADUS)
TD Cowen Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $141
TD Cowen Maintains Addus HomeCare(ADUS.US) With Buy Rating, Raises Target Price to $141
Addus HomeCare Price Target Raised to $145.00/Share From $143.00 by Stephens & Co.
Addus HomeCare Is Maintained at Outperform by RBC Capital
Addus HomeCare Analyst Ratings
Oppenheimer Maintains Addus HomeCare(ADUS.US) With Buy Rating, Maintains Target Price $145
RBC Capital Maintains Addus HomeCare(ADUS.US) With Buy Rating, Cuts Target Price to $136
A Quick Look at Today's Ratings for Addus HomeCare(ADUS.US), With a Forecast Between $83 to $145
Barclays Maintains Addus HomeCare(ADUS.US) With Sell Rating, Maintains Target Price $83
Macquarie Maintains Addus HomeCare(ADUS.US) With Buy Rating